The post-listing market capitalisation for the company stands at Rs 29,848 crore, helping it break into the top 10 valuable pharma firms in the country
The Rs 6,480-crore IPO of Gland Pharma managed to sail through solely on the back of institutional investor demand.
All that happened in the markets today
The retail and HNI portion of the IPO were subscribed just 51 per cent and 24 per cent, respectively
Institutional portion sees 6.4x subscription; HNIs, retail investors give issue a miss
Offering received bids for 6.4 mn shares as against 30 mn on offer
While prospects remain strong led by niche products and a differentiated business model, relatively rich valuations leave limited scope for upside in near-term
On Friday, the company had allotted Rs 1,944 crore worth of shares to anchor investors
The grey market premium for Gland Pharma has come off sharply from Rs 185 per share to just Rs 60 per share
Fosun-owned Gland Pharma sets price band for its IPO at Rs 1,490-1,500 per share
Gland Pharma, which announced itsabout Rs 6,500 crore IPO, has set a price band of Rs 1,490-1,500 per share (face value of Rs one) and the issue will be open on November 9, an official said
Apart from the fresh issue, there is an offer for sale (OFS) of a little over 34 million shares as part of the IPO
Hyderabad-based Gland, founded in 1978, specializes in injectable drugs such as antibiotics, oncology and cardiology treatments
The deal was announced last July when Shanghai Fosun agreed to buy an 86% stake in Gland Pharma
Target firm Gland Pharma makes a variety of injectables, which are harder to make than regular medicines